Atara Biotherapeutics is a biotechnology business based in the US. Atara Biotherapeutics shares (ATRA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.69 – a decrease of 5.41% over the previous week. Atara Biotherapeutics employs 165 staff and has a trailing 12-month revenue of around $62.4 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $7.69 |
|---|---|
| 52-week range | $4.97 - $45.75 |
| 50-day moving average | $8.22 |
| 200-day moving average | $13.70 |
| Wall St. target price | $90.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-39.00 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.69 from 2024-10-04
| 1 week (2024-10-01) | 0.79% |
|---|---|
| 1 month (2024-09-06) | -18.80% |
| 3 months (2024-07-08) | -3.39% |
| 6 months (2024-04-08) | 917.20% |
| 1 year (2023-10-06) | 445.39% |
|---|---|
| 2 years (2022-10-07) | 101.31% |
| 3 years (2021-10-07) | 17.62 |
| 5 years (2019-10-08) | 13.6 |
| Revenue TTM | $62.4 million |
|---|---|
| Gross profit TTM | $63.6 million |
| Return on assets TTM | -57.48% |
| Return on equity TTM | -2014.86% |
| Profit margin | -290.2% |
| Book value | $-22.61 |
| Market Capitalization | $43.3 million |
TTM: trailing 12 months
We're not expecting Atara Biotherapeutics to pay a dividend over the next 12 months.
Atara Biotherapeutics's shares were split on a 1:25 basis on 19 June 2024. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Atara Biotherapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Atara Biotherapeutics shares which in turn could have impacted Atara Biotherapeutics's share price.
Over the last 12 months, Atara Biotherapeutics's shares have ranged in value from as little as $4.965 up to $45.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atara Biotherapeutics's is 0.498. This would suggest that Atara Biotherapeutics's shares are less volatile than average (for this exchange).
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Check out the best-performing ETFs so far in 2024.